ciprofibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists 658 52214-84-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ciprofibrate
  • lipanor
  • oroxadin
Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol.
  • Molecular weight: 289.15
  • Formula: C13H14Cl2O3
  • CLOGP: 3.18
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -4.57
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 33
kinase-selectivity-class EIF2AK3,GRK2 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 18, 2009 UK Medicines and Healthcare Products Regulatory Agency (MHRA) Winthrop Pharmaceuticals UK Limited

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mucosal pain 33.79 31.61 4 600 54 110588641

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AB08 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Fibrates
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D002273 Carcinogens
MeSH PA D009676 Noxae
MeSH PA D020025 Peroxisome Proliferators
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35679 antilipemic drug

Related Drugs by ATC class:

C10AB Fibrates 11 drugs
aluminium clofibratebezafibratecholine fenofibrateclofibrateclofibrideetofibratefenofibrategemfibrozilpemafibrateronifibratesimfibrate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.71 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peroxisome proliferator-activated receptor alpha Nuclear hormone receptor AGONIST EC50 6.05 CHEMBL SCIENTIFIC LITERATURE

External reference:

IDSource
D03521 KEGG_DRUG
21149 RXNORM
C0055775 UMLSCUI
CHEBI:50867 CHEBI
CHEMBL557555 ChEMBL_ID
DB09064 DRUGBANK_ID
C019304 MESH_SUPPLEMENTAL_RECORD_UI
2763 PUBCHEM_CID
3438 IUPHAR_LIGAND_ID
4057 INN_ID
F8252JGO9S UNII
004087 NDDF
320016006 SNOMEDCT_US
395957009 SNOMEDCT_US
F8252JGO9S INXIGHT DRUGS

Pharmaceutical products:

None